AONC logo

American Oncology Network, Inc. (AONC)

Nur zu Informationszwecken. Keine Finanzberatung. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.

Mit einem Kurs von $ ist American Oncology Network, Inc. (AONC) ein Healthcare-Unternehmen mit einer Bewertung von 0. Die Aktie erzielt 50/100, eine moderate Bewertung basierend auf 9 quantitativen KPIs.

Zuletzt analysiert: 16. März 2026
50/100 KI-Bewertung

American Oncology Network, Inc. (AONC) Gesundheitswesen & Pipeline-Uebersicht

CEOTodd Schonherz
Mitarbeiter1914
HauptsitzFort Myers, US
IPO-Jahr2021

American Oncology Network, Inc. delivers comprehensive oncology services, including lab, pathology, pharmacy, and care management. Operating within the U.S. medical care facilities sector, AONC focuses on integrated cancer care solutions, facing competition from established healthcare providers and evolving market dynamics.

Datenherkunft | Finanzdaten Quantitative Analyse NASDAQ Analyse: 16. März 2026

Investmentthese

American Oncology Network, Inc. presents a mixed investment case. AONC's integrated oncology service model, including lab, pathology, and pharmacy services, aims to improve patient care and streamline operations for affiliated practices. However, with a high P/E ratio of 655.43 and a near-zero profit margin, the company's valuation appears stretched. The company's beta of 0.76 suggests lower volatility compared to the market. Growth catalysts include expanding its network of affiliated practices and enhancing service offerings. Potential risks include increasing competition in the oncology services market and regulatory changes affecting healthcare providers. Investors should closely monitor AONC's ability to improve profitability and execute its growth strategy effectively.

Basierend auf FMP-Finanzdaten und quantitativer Analyse

Wichtige Highlights

  • Market capitalization of $0.35 billion indicates a mid-sized player in the medical care facilities sector.
  • P/E ratio of 655.43 suggests the stock may be overvalued relative to its earnings.
  • Gross margin of 8.2% indicates relatively low profitability in its core operations.
  • Beta of 0.76 suggests the stock is less volatile than the overall market.
  • The company does not offer a dividend, which may deter income-focused investors.

Wettbewerber & Vergleichsunternehmen

Staerken

  • Integrated service model offering comprehensive oncology care.
  • Network of affiliated community oncology practices.
  • In-house specialty pharmacy services providing patient support.
  • Care management support services including nutrition guidance.

Schwaechen

  • High P/E ratio suggesting overvaluation.
  • Low gross margin indicating profitability challenges.
  • Dependence on affiliated practices for patient volume.
  • Limited geographic diversification.

Katalysatoren

  • Ongoing: Expansion of the network of affiliated oncology practices, increasing patient reach and service volume.
  • Ongoing: Enhancement of in-house specialty pharmacy services, improving patient adherence and outcomes.
  • Ongoing: Development and expansion of care management support services, enhancing patient outcomes and reducing healthcare costs.
  • Upcoming: Potential partnerships with other healthcare providers and organizations, expanding service offerings and market reach.
  • Upcoming: Investment in advanced diagnostic technologies and laboratory services, improving cancer diagnoses and treatment.

Risiken

  • Ongoing: Increasing competition in the oncology services market, potentially impacting market share and profitability.
  • Ongoing: Regulatory changes affecting healthcare providers, potentially increasing compliance costs and operational challenges.
  • Ongoing: Reimbursement pressures from insurance companies, potentially reducing revenue and profitability.
  • Potential: Economic downturn impacting patient access to care, potentially reducing patient volume and revenue.
  • Potential: Limited liquidity in the OTC market, making it difficult to buy or sell shares at desired prices.

Wachstumschancen

  • Expanding the network of affiliated oncology practices represents a significant growth opportunity for AONC. By partnering with more community-based practices, AONC can increase its patient reach and service volume. The market for oncology services is expanding, driven by an aging population and advancements in cancer treatment. AONC can leverage its integrated service model to attract new practices and enhance its market presence. This expansion could lead to increased revenue and improved economies of scale, with a potential timeline of 2-3 years to realize significant gains.
  • Enhancing in-house specialty pharmacy services presents another growth avenue. By offering patient education, financial assistance, and 24/7 support, AONC can improve patient adherence and outcomes. The specialty pharmacy market is growing rapidly, driven by the increasing use of targeted therapies and personalized medicine. AONC can capitalize on this trend by expanding its pharmacy capabilities and offering specialized services to its patients. This enhancement could lead to increased revenue and improved patient satisfaction, with a potential timeline of 1-2 years to implement fully.
  • Developing and expanding care management support services, including nutrition guidance, can improve patient outcomes and reduce healthcare costs. By providing comprehensive care management, AONC can enhance patient adherence to treatment plans and prevent complications. The market for care management services is growing, driven by the increasing focus on value-based care and the need to improve patient outcomes. AONC can leverage its expertise in oncology care to develop and implement effective care management programs. This development could lead to improved patient outcomes and reduced healthcare costs, with a potential timeline of 2-3 years to realize significant benefits.
  • Investing in advanced diagnostic technologies and laboratory services can enhance AONC's capabilities and attract more patients. By offering state-of-the-art diagnostic services, AONC can improve the accuracy and timeliness of cancer diagnoses. The market for diagnostic technologies is growing rapidly, driven by advancements in genomics and personalized medicine. AONC can capitalize on this trend by investing in advanced technologies and expanding its laboratory capabilities. This investment could lead to improved patient outcomes and increased revenue, with a potential timeline of 3-5 years to implement fully.
  • Exploring strategic partnerships with other healthcare providers and organizations can expand AONC's reach and service offerings. By collaborating with hospitals, research institutions, and other healthcare providers, AONC can offer a more comprehensive range of services to its patients. The market for healthcare partnerships is growing, driven by the increasing need for integrated care and the desire to improve patient outcomes. AONC can leverage its expertise in oncology care to forge strategic partnerships and expand its market presence. This collaboration could lead to increased revenue and improved patient satisfaction, with a potential timeline of 2-4 years to realize significant gains.

Chancen

  • Expanding the network of affiliated oncology practices.
  • Enhancing in-house specialty pharmacy services.
  • Developing and expanding care management support services.
  • Investing in advanced diagnostic technologies and laboratory services.

Risiken

  • Increasing competition in the oncology services market.
  • Regulatory changes affecting healthcare providers.
  • Reimbursement pressures from insurance companies.
  • Economic downturn impacting patient access to care.

Wettbewerbsvorteile

  • Integrated service model providing comprehensive oncology care.
  • Network of affiliated community oncology practices.
  • In-house specialty pharmacy services offering patient support and education.

Ueber AONC

American Oncology Network, Inc. (AONC) was founded in 2017 and is headquartered in Fort Myers, Florida. The company operates in the medical care facilities sector, providing a range of oncology services through its subsidiaries across the United States. AONC’s core offerings include laboratory services for routine and specialized testing, in-house professional and technical pathology services delivering timely reports, and in-house specialty pharmacy services that offer patient education, financial assistance, and round-the-clock patient support. Additionally, AONC provides care management support services, including nutrition guidance, to enhance patient outcomes. By integrating these services, AONC aims to deliver comprehensive and coordinated cancer care to patients, improving their overall experience and treatment efficacy. The company focuses on partnering with community oncology practices, providing them with resources and expertise to enhance their service offerings and operational efficiency. AONC's business model emphasizes a patient-centric approach, ensuring access to advanced treatments and personalized care plans. The company's growth strategy involves expanding its network of affiliated practices and enhancing its service capabilities to meet the evolving needs of cancer patients.

Was das Unternehmen tut

  • Provides laboratory services for routine and specialized testing.
  • Offers in-house professional and technical pathology services.
  • Delivers complete, accurate, and timely pathology reports.
  • Provides in-house specialty pharmacy services.
  • Offers patient education and financial assistance.
  • Provides 24/7 patient assistance through its pharmacy services.
  • Offers care management support services, including nutrition guidance.

Geschaeftsmodell

  • Generates revenue through providing oncology services, including laboratory, pathology, and pharmacy services.
  • Partners with community oncology practices, providing them with resources and expertise.
  • Focuses on integrating services to deliver comprehensive and coordinated cancer care.

Branchenkontext

American Oncology Network, Inc. operates within the medical care facilities sector, which is experiencing growth due to the increasing prevalence of cancer and advancements in treatment options. The market is competitive, with established players and smaller specialized providers. Trends include a shift towards personalized medicine, integrated care models, and the adoption of advanced technologies. AONC's focus on providing comprehensive oncology services positions it to capitalize on these trends, but it faces competition from larger healthcare systems and other oncology networks. The industry is also subject to regulatory changes and reimbursement pressures, which can impact profitability and growth.

Wichtige Kunden

  • Cancer patients seeking treatment and care.
  • Community oncology practices affiliated with the network.
  • Healthcare providers and organizations seeking partnerships.
KI-Zuversicht: 71% Aktualisiert: 16. März 2026

Finanzdaten

Chart & Info

American Oncology Network, Inc. (AONC) Aktienkurs: Price data unavailable

Aktuelle Nachrichten

Analystenkonsens

Konsens-Bewertung

Aggregierte Kauf-/Halten-/Verkauf-Empfehlungen von Benzinga, Yahoo Finance und Finnhub fuer AONC.

Kursziele

Wall-Street-Kurszielanalyse fuer AONC.

MoonshotScore

50/100

Was bedeutet diese Bewertung?

Der MoonshotScore bewertet das Wachstumspotenzial von AONC auf einer Skala von 0-100 ueber mehrere Faktoren wie Innovation, Marktdisruption, finanzielle Gesundheit und Momentum.

Fuehrung: Todd Schonherz

CEO

Todd Schonherz serves as the CEO of American Oncology Network, Inc. His background includes extensive experience in healthcare management and operations. He has a proven track record of leading and growing healthcare organizations. Schonherz's expertise spans strategic planning, financial management, and operational efficiency. His leadership is focused on driving innovation and improving patient outcomes within the oncology services sector. He is responsible for managing a workforce of 1914 employees.

Erfolgsbilanz: Under Todd Schonherz's leadership, American Oncology Network, Inc. has focused on expanding its network of affiliated practices and enhancing its service offerings. Key milestones include the integration of advanced diagnostic technologies and the development of comprehensive care management programs. Schonherz has also overseen the implementation of patient-centric initiatives aimed at improving the overall patient experience. His strategic decisions have contributed to the company's growth and market presence.

AONC OTC-Marktinformationen

OTC Other, also known as the Pink Market, represents the lowest tier of the OTC market. Companies in this tier often do not meet minimum financial standards and may not be required to file regular reports with the SEC. This lack of regulatory oversight can lead to increased risks for investors. Stocks in the OTC Other tier are often thinly traded, making it difficult to buy or sell shares without significantly impacting the price. Investing in OTC Other stocks requires careful due diligence and a high tolerance for risk compared to stocks listed on major exchanges like the NYSE or NASDAQ.

  • OTC-Stufe: OTC Other
  • Offenlegungsstatus: Unknown
Liquiditaet: Liquidity for AONC shares on the OTC market is likely limited. The trading volume may be low, and the bid-ask spread could be wide, making it challenging to execute trades at desired prices. This lack of liquidity can increase the risk of significant price fluctuations and make it difficult to exit a position quickly. Investors should be aware of these liquidity constraints before investing in AONC.
OTC-Risikofaktoren:
  • Limited regulatory oversight and disclosure requirements.
  • Potential for fraud or manipulation due to lack of transparency.
  • Thin trading volume and wide bid-ask spreads.
  • Higher risk of financial instability or bankruptcy.
  • Difficulty in obtaining reliable financial information.
Sorgfaltspruefung-Checkliste:
  • Verify the company's registration and legal status.
  • Obtain and review available financial statements.
  • Assess the company's management team and their experience.
  • Research the company's business model and competitive landscape.
  • Evaluate the company's risk factors and potential liabilities.
  • Consult with a financial advisor before investing.
  • Understand the limitations of OTC market trading.
Legitimitaetssignale:
  • The company has been in operation since 2017.
  • The company has a large employee base of 1914.
  • The company provides essential oncology services.
  • The company has a CEO, Todd Schonherz, managing the operations.

American Oncology Network, Inc. Aktie: Wichtige Fragen beantwortet

What are the key factors to evaluate for AONC?

American Oncology Network, Inc. (AONC) currently holds an AI score of 50/100, indicating moderate score. Key strength: Integrated service model offering comprehensive oncology care.. Primary risk to monitor: Ongoing: Increasing competition in the oncology services market, potentially impacting market share and profitability.. This is not financial advice.

How frequently does AONC data refresh on this page?

AONC prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.

What has driven AONC's recent stock price performance?

Recent price movement in American Oncology Network, Inc. (AONC) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Integrated service model offering comprehensive oncology care.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.

Should investors consider AONC overvalued or undervalued right now?

Determining whether American Oncology Network, Inc. (AONC) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.

What research should beginners do before buying AONC?

Before investing in American Oncology Network, Inc. (AONC), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).

Why might investors consider adding AONC to a portfolio?

Potential reasons to consider American Oncology Network, Inc. (AONC) depend on individual investment goals and risk tolerance. A key strength identified by analysis: Integrated service model offering comprehensive oncology care.. Additionally: Network of affiliated community oncology practices.. Always weigh potential rewards against risks and diversify across holdings. This is not financial advice.

Can I buy fractional shares of AONC?

Yes, most major brokerages offer fractional shares of American Oncology Network, Inc. (AONC) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.

How can I track AONC's earnings and financial reports?

American Oncology Network, Inc. (AONC) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Setting up alerts through your brokerage for AONC earnings announcements is recommended.

Haftungsausschluss: Dieser Inhalt dient ausschliesslich zu Informationszwecken und stellt keine Anlageberatung dar. Fuehren Sie immer Ihre eigene Recherche durch und konsultieren Sie einen Finanzberater.

Offizielle Ressourcen

Analyse aktualisiert am KI-Bewertung taeglich aktualisiert
Datenquellen & Methodik
Marktdaten bereitgestellt von Financial Modeling Prep & Yahoo Finance. KI-Analyse durch proprietaere Algorithmen von Stock Expert AI. Technische Indikatoren nach branchenueblichen Berechnungsstandards. Zuletzt aktualisiert: .

Daten dienen ausschliesslich zu Informationszwecken.

Analysehinweise
  • OTC data may be less reliable than exchange-listed data.
  • AI analysis pending for AONC.
Datenquellen

Popular Stocks